ATE510929T1 - Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozyten - Google Patents
Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozytenInfo
- Publication number
- ATE510929T1 ATE510929T1 AT06772657T AT06772657T ATE510929T1 AT E510929 T1 ATE510929 T1 AT E510929T1 AT 06772657 T AT06772657 T AT 06772657T AT 06772657 T AT06772657 T AT 06772657T AT E510929 T1 ATE510929 T1 AT E510929T1
- Authority
- AT
- Austria
- Prior art keywords
- tnf
- cancer
- leukocytes
- chemokines
- immune response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68874405P | 2005-06-08 | 2005-06-08 | |
US73550805P | 2005-11-11 | 2005-11-11 | |
PCT/US2006/022427 WO2006133399A1 (en) | 2005-06-08 | 2006-06-08 | METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE510929T1 true ATE510929T1 (de) | 2011-06-15 |
Family
ID=37498782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06772657T ATE510929T1 (de) | 2005-06-08 | 2006-06-08 | Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozyten |
AT08008370T ATE493515T1 (de) | 2005-06-08 | 2006-06-08 | Verfahren zur vorhersage der immunreaktion auf neoplastische krankheiten auf der grundlage des mrna-ausdrucksprofil in neoplastischen zellen und stimulierten leukozyten |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08008370T ATE493515T1 (de) | 2005-06-08 | 2006-06-08 | Verfahren zur vorhersage der immunreaktion auf neoplastische krankheiten auf der grundlage des mrna-ausdrucksprofil in neoplastischen zellen und stimulierten leukozyten |
Country Status (7)
Country | Link |
---|---|
US (1) | US7741023B2 (de) |
EP (2) | EP1964931B1 (de) |
JP (1) | JP4800384B2 (de) |
CN (1) | CN101194027B (de) |
AT (2) | ATE510929T1 (de) |
DE (1) | DE602006019312D1 (de) |
WO (1) | WO2006133399A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080261207A1 (en) * | 2004-05-25 | 2008-10-23 | Masato Mitsuhashi | Method of Measuring Cancer Susceptibility |
JP4772055B2 (ja) * | 2004-10-20 | 2011-09-14 | 日立化成工業株式会社 | mRNAの定量により薬剤の投与を選定する方法 |
US20080206761A1 (en) * | 2005-04-28 | 2008-08-28 | Masato Mitsuhashi | Ex Vivo Gene Expression in Whole Blood as a Model of Assessment of Individual Variation to Dietary Supplements |
DE102007045562A1 (de) * | 2007-09-24 | 2009-04-02 | Robert Bosch Gmbh | Steuereinrichtung für eine Anzeigeeinrichtung einer Einparkeinrichtung und Verfahren zur Darstellung |
JP2011502535A (ja) * | 2007-11-14 | 2011-01-27 | 日立化成工業株式会社 | 末梢血白血球における、Fc受容体を介した腫瘍壊死因子スーパーファミリーmRNA発現 |
JP5775874B2 (ja) * | 2009-08-28 | 2015-09-09 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
JP5706913B2 (ja) * | 2009-12-16 | 2015-04-22 | 日立化成株式会社 | 攻撃的及び防御的免疫マーカーのexvivo誘導により宿主免疫機能を特徴付けるための方法 |
EP2561368B1 (de) | 2010-04-19 | 2017-08-02 | Biomarker Strategies, LLC. | Zusammensetzungen und verfahren zur vorhersage von arzneimittelempfindlichkeit und -resistenz sowie krankheitsfortschritt |
WO2011131246A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
WO2012007783A1 (en) * | 2010-07-13 | 2012-01-19 | Institut Gustave Roussy | Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject |
US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
WO2011140125A1 (en) | 2010-05-07 | 2011-11-10 | Hitachi Chemical Co., Ltd. | Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers |
EP2388312A1 (de) * | 2010-05-17 | 2011-11-23 | Curetis AG | Universell anwendbarer Lysepuffer und Verarbeitungsverfahren zur Lyse von Körperproben |
WO2011156734A2 (en) | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
JP5755326B2 (ja) | 2010-06-11 | 2015-07-29 | 日立化成株式会社 | 腎機能の特徴を決定する方法 |
WO2012170037A1 (en) | 2011-06-10 | 2012-12-13 | Hitachi Chemical Co., Ltd. | Vesicle capturing devices and methods for using same |
EP2734233B1 (de) * | 2011-07-18 | 2017-11-01 | Hitachi Chemical Co., Ltd. | Verfahren zur vorhersage des ansprechens eines wirtes auf krebsimmuntherapien durch ex-vivo-induktion von mit leukozytenfunktionen assoziierten mrnas |
AU2012301664A1 (en) * | 2011-08-31 | 2014-02-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
CA2883810C (en) * | 2012-09-06 | 2017-10-31 | Hitachi Chemical Co., Ltd. | Methods for assessment of peptide-specific immunity |
JP2014057582A (ja) * | 2012-09-17 | 2014-04-03 | Hitachi Chemical Co Ltd | 細胞傷害活性を予測するための方法及びキット |
CN103193886A (zh) * | 2013-04-14 | 2013-07-10 | 浙江大学 | 鼠抗人T细胞抗原ZCH-2B8a荧光标记单抗的用途 |
WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
WO2016077537A1 (en) | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
WO2017040520A1 (en) | 2015-08-31 | 2017-03-09 | Hitachi Chemical Co., Ltd. | Molecular methods for assessing urothelial disease |
AU2017261353A1 (en) * | 2016-05-05 | 2018-11-08 | Nantomics, Llc | Checkpoint failure and methods therefor |
US20200041493A1 (en) * | 2016-10-14 | 2020-02-06 | StickyCell Pty Ltd | Leukocyte adhesive function assays, devices and/or uses |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925572A (en) | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
US4880548A (en) | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
EP0938320B2 (de) | 1996-03-26 | 2014-06-18 | Michael S. Kopreski | Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden |
US5683698A (en) | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
US7514232B2 (en) | 1996-12-06 | 2009-04-07 | Becton, Dickinson And Company | Method for detecting T cell response to specific antigens in whole blood |
US6183951B1 (en) | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
US20020006613A1 (en) | 1998-01-20 | 2002-01-17 | Shyjan Andrew W. | Methods and compositions for the identification and assessment of cancer therapies |
AU768189B2 (en) | 1999-06-15 | 2003-12-04 | Nutri-Logics, Inc. | Nutrient formulations for disease reduction, and related treatment and component screening methods |
US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6549616B1 (en) * | 2000-03-20 | 2003-04-15 | Serconet Ltd. | Telephone outlet for implementing a local area network over telephone lines and a local area network using such outlets |
US20020048566A1 (en) | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
US20020182274A1 (en) | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
KR20040064275A (ko) | 2001-11-09 | 2004-07-16 | 소스 프리시전 메디슨, 인코포레이티드 | 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 |
US7767390B2 (en) | 2001-11-20 | 2010-08-03 | Oncomedx, Inc. | Methods for evaluating drug-resistance gene expression in the cancer patient |
US7871619B2 (en) * | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
FI20020078A (fi) | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
US6878518B2 (en) | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
US7745180B2 (en) | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
CA2526950C (en) | 2002-05-27 | 2012-06-26 | Leif Hakansson | Method for determining immune system affecting compounds |
AU2002953533A0 (en) | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
US20080261207A1 (en) | 2004-05-25 | 2008-10-23 | Masato Mitsuhashi | Method of Measuring Cancer Susceptibility |
WO2006110091A1 (en) * | 2005-04-15 | 2006-10-19 | Therim Diagnostica Ab | Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6 |
US20080206761A1 (en) | 2005-04-28 | 2008-08-28 | Masato Mitsuhashi | Ex Vivo Gene Expression in Whole Blood as a Model of Assessment of Individual Variation to Dietary Supplements |
AU2006294477A1 (en) | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
-
2006
- 2006-06-08 AT AT06772657T patent/ATE510929T1/de not_active IP Right Cessation
- 2006-06-08 CN CN2006800202986A patent/CN101194027B/zh not_active Expired - Fee Related
- 2006-06-08 EP EP08008370A patent/EP1964931B1/de not_active Not-in-force
- 2006-06-08 DE DE602006019312T patent/DE602006019312D1/de active Active
- 2006-06-08 US US11/917,151 patent/US7741023B2/en not_active Expired - Fee Related
- 2006-06-08 JP JP2008515958A patent/JP4800384B2/ja not_active Expired - Fee Related
- 2006-06-08 AT AT08008370T patent/ATE493515T1/de not_active IP Right Cessation
- 2006-06-08 WO PCT/US2006/022427 patent/WO2006133399A1/en active Application Filing
- 2006-06-08 EP EP06772657A patent/EP1904657B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
CN101194027B (zh) | 2012-10-24 |
EP1964931B1 (de) | 2010-12-29 |
EP1904657B1 (de) | 2011-05-25 |
CN101194027A (zh) | 2008-06-04 |
JP2008543286A (ja) | 2008-12-04 |
EP1964931A2 (de) | 2008-09-03 |
EP1964931A3 (de) | 2009-01-21 |
DE602006019312D1 (de) | 2011-02-10 |
US20090111128A1 (en) | 2009-04-30 |
WO2006133399A1 (en) | 2006-12-14 |
ATE493515T1 (de) | 2011-01-15 |
EP1904657A4 (de) | 2008-12-31 |
JP4800384B2 (ja) | 2011-10-26 |
WO2006133399A9 (en) | 2007-03-01 |
EP1904657A1 (de) | 2008-04-02 |
US7741023B2 (en) | 2010-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE510929T1 (de) | Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozyten | |
Schalper | PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer | |
Thiery et al. | Tumor dissemination: an EMT affair | |
Thompson et al. | Platelet-endothelial cell adhesion molecule-1 (PECAM-1)–deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane | |
Holden et al. | ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process | |
Criscitiello et al. | Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer | |
JP2013517461A5 (de) | ||
DK1631318T3 (da) | Magnetiske nanopartikler bundet til en ligand | |
Rochigneux et al. | Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma | |
Hu et al. | Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal B-like (HER2−) breast cancer | |
Carone et al. | Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence | |
Liu et al. | PD-1 related transcriptome profile and clinical outcome in diffuse gliomas | |
Robertson et al. | The role of AEG-1 in the development of liver cancer | |
Xia et al. | The potential of CXCL5 as a target for liver cancer–what do we know so far? | |
Hu et al. | Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma | |
Shuman et al. | A north–south moisture dipole at multi-century scales in the Central and Southern Rocky Mountains, USA, during the late Holocene | |
Munster et al. | PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (PT) populations defined by predictive markers (study P3K112826) | |
Kramer et al. | Tyrosine kinase inhibition in HPV-related squamous cell carcinoma reveals beneficial expression of cKIT and SRC | |
Chiodin et al. | High surface IgM levels associate with shorter response duration and bypass of the BTK blockade during ibrutinib therapy in CLL patients | |
Cao et al. | Expression of B7-H2 on CD8+ T cells in colorectal cancer microenvironment and its clinical significance | |
Gomez-Aleza et al. | Inhibition of RANK signaling as a potential immunotherapy in breast cancer | |
Dagogo-Jack et al. | Overcoming on-target resistance to tyrosine kinase inhibitors in lung cancer | |
Brodt | Surviving host innate immunity: Cancer cells can turn a deadly assault into an advantage | |
Cha et al. | Shuffling the deck with CTLA-4 therapy: deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients | |
Lacouture et al. | Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |